Stryker Corp. (NYSE:SYK) VP Yin C. Becker sold 12,000 shares of the business’s stock in a transaction on Wednesday, October 12th. The shares were sold at an average price of $114.03, for a total transaction of $1,368,360.00. Following the completion of the sale, the vice president now owns 28,939 shares in the company, valued at approximately $3,299,914.17. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
Stryker Corp. (NYSE:SYK) opened at 113.57 on Tuesday. The firm’s 50-day moving average price is $115.20 and its 200-day moving average price is $114.25. Stryker Corp. has a 52-week low of $86.68 and a 52-week high of $123.55. The firm has a market cap of $42.51 billion, a P/E ratio of 26.77 and a beta of 0.72.
Stryker Corp. (NYSE:SYK) last posted its earnings results on Thursday, July 21st. The medical technology company reported $1.39 EPS for the quarter, beating the consensus estimate of $1.37 by $0.02. The firm earned $2.84 billion during the quarter, compared to the consensus estimate of $2.79 billion. Stryker Corp. had a return on equity of 23.61% and a net margin of 15.33%. Equities research analysts expect that Stryker Corp. will post $5.76 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Monday, October 31st. Shareholders of record on Friday, September 30th will be given a $0.38 dividend. The ex-dividend date is Wednesday, September 28th. This represents a $1.52 annualized dividend and a yield of 1.34%. Stryker Corp.’s dividend payout ratio is presently 35.85%.
A number of institutional investors have recently bought and sold shares of the stock. Lazard Asset Management LLC purchased a new position in Stryker Corp. during the first quarter valued at approximately $272,490,000. Winslow Capital Management LLC bought a new position in shares of Stryker Corp. during the second quarter worth about $174,599,000. Capital Research Global Investors increased its position in shares of Stryker Corp. by 3.4% in the second quarter. Capital Research Global Investors now owns 32,980,782 shares of the medical technology company’s stock worth $3,952,087,000 after buying an additional 1,095,549 shares during the period. BlackRock Fund Advisors increased its position in shares of Stryker Corp. by 20.1% in the second quarter. BlackRock Fund Advisors now owns 6,280,516 shares of the medical technology company’s stock worth $752,594,000 after buying an additional 1,051,648 shares during the period. Finally, Emerald Acquisition Ltd. bought a new position in shares of Stryker Corp. during the second quarter worth about $104,111,000. Hedge funds and other institutional investors own 75.50% of the company’s stock.
SYK has been the topic of several recent analyst reports. SunTrust Banks Inc. initiated coverage on shares of Stryker Corp. in a research note on Thursday, October 13th. They issued a “buy” rating and a $140.00 target price on the stock. Zacks Investment Research cut Stryker Corp. from a “hold” rating to a “sell” rating in a report on Tuesday, September 27th. Needham & Company LLC reaffirmed a “hold” rating on shares of Stryker Corp. in a report on Sunday, July 24th. Piper Jaffray Cos. lifted their price target on Stryker Corp. from $120.00 to $135.00 and gave the company an “overweight” rating in a report on Friday, July 22nd. Finally, Brean Capital reaffirmed a “buy” rating and issued a $125.00 price target (up from $121.00) on shares of Stryker Corp. in a report on Monday, July 25th. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $117.91.
About Stryker Corp.